NASDAQ · OPK
Healthcare · Medical - Diagnostics & Research
$1.64
Up+$0.03 (+1.86%)
Updated Sep 7, 2026, 5:15 PM
SID Score
6.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
OPK closed at $1.64 after 20 trading sessions, up 17.99% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $1.59 | $1.65 | $1.57 | $1.64 | 2.35M |
| Sep 3, 2026 | $1.71 | $1.73 | $1.59 | $1.61 | 7.55M |
| Sep 2, 2026 | $1.55 | $1.715 | $1.54 | $1.69 | 7.14M |
| Sep 1, 2026 | $1.47 | $1.53 | $1.47 | $1.52 | 3.06M |
| Aug 31, 2026 | $1.48 | $1.49 | $1.455 | $1.47 | 2.36M |
| Aug 28, 2026 | $1.49 | $1.50 | $1.46 | $1.48 | 2.42M |
| Aug 27, 2026 | $1.49 | $1.53 | $1.49 | $1.50 | 2.71M |
| Aug 26, 2026 | $1.50 | $1.52 | $1.47 | $1.51 | 2.89M |
| Aug 25, 2026 | $1.49 | $1.51 | $1.4717 | $1.49 | 2.24M |
| Aug 24, 2026 | $1.49 | $1.51 | $1.47 | $1.48 | 1.92M |
| Aug 21, 2026 | $1.47 | $1.5197 | $1.455 | $1.48 | 2.66M |
| Aug 20, 2026 | $1.44 | $1.475 | $1.42 | $1.46 | 2.54M |
| Aug 19, 2026 | $1.37 | $1.48 | $1.36 | $1.46 | 3.37M |
| Aug 18, 2026 | $1.38 | $1.39 | $1.355 | $1.36 | 1.6M |
| Aug 17, 2026 | $1.35 | $1.38 | $1.32 | $1.36 | 3.04M |
| Aug 14, 2026 | $1.39 | $1.40 | $1.32 | $1.38 | 3.28M |
| Aug 13, 2026 | $1.41 | $1.425 | $1.39 | $1.40 | 1.62M |
| Aug 12, 2026 | $1.39 | $1.4068 | $1.38 | $1.39 | 1.83M |
| Aug 11, 2026 | $1.39 | $1.4087 | $1.37 | $1.39 | 1.84M |
| Aug 10, 2026 | $1.36 | $1.40 | $1.36 | $1.39 | 2.56M |
The latest Smart Investors Daily articles mentioning OPK.
OPK research
Company profile and research snapshot.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 29, 2026 | Barrington Research | Market Perform | — |
| Mar 2, 2026 | Barrington Research | Outperform | — |
| Nov 20, 2025 | JP Morgan | Neutral | — |
| Oct 31, 2025 | Jefferies | Hold | — |
| Oct 30, 2025 | Barrington Research | Outperform | — |
No generated briefing is available yet.
Benzinga · Aug 13, 2026
The newly issued notes are secured by OPKO’s royalty interests arising under its mazdutide license agreement with Eli Lilly and Company and mature in 2044, consistent with the maturity of OPKO’s existing HCRx notes
SeekingAlpha · Aug 1, 2026
Opko Health beat earnings and raised guidance, but one-off gains mask weak core trends. Click here to read more about OPK.
SeekingAlpha · Jul 27, 2026
OPKO Health, Inc. (OPK) Q2 2026 Earnings Call July 27, 2026 4:30 PM EDTCompany ParticipantsPhillip Frost - Chairman of the Board & CEOElias Zerhouni -...
ChartMill · Jul 27, 2026
OPKO Health beat Q2 estimates with $163.5M revenue and narrower -$0.01 EPS, sending shares up 16% after-hours.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OPK.
